Hyderabad API maker & CDMO with 3 US FDA-audited plants, 100+ APIs, serving 80+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 697 | 774 | 828 | 981 | 1.3k | 1.5k | 1.6k | 1.9k |
| Borrowings | 264 | 182 | 241 | 128 | 95 | 157 | 265 | 301 |
| Other Liabilities | 257 | 356 | 302 | 457 | 454 | 498 | 649 | 754 |
| Total Liabilities | 1.2k | 1.3k | 1.4k | 1.6k | 1.8k | 2.2k | 2.5k | 2.9k |
| AssetsFixed Assets | 653 | 716 | 767 | 758 | 824 | 955 | 1.1k | 1.2k |
| CWIP | 24 | 17 | 20 | 41 | 46 | 48 | 140 | 211 |
| Investments | 8 | 7 | 4 | 1 | 1 | 109 | 114 | 2 |
| Other Assets | 547 | 585 | 592 | 781 | 962 | 1.1k | 1.2k | 1.5k |
| Total Assets | 1.2k | 1.3k | 1.4k | 1.6k | 1.8k | 2.2k | 2.5k | 2.9k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 70 | 57 | 189 | 60 | 237 | 261 | 317 | 347 |
| Cash from Investing | -77 | -49 | -84 | -95 | -61 | -150 | -298 | -423 |
| Cash from Financing | 12 | -5 | -114 | 38 | -136 | -69 | 25 | 21 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 7 | 9 | 84 | -37 | 173 | 119 | 112 | -50 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (42.4×) and current (65.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 30.6% growth and a 42× exit, ₹18434 only delivers your return if you pay ₹21,342. The price is currently baking in 27% growth.
EPS grows 30.6%/yr for 5 years, then fades to 6% over 2, exits at 42×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 30.6% | 370.51 |
| FY28 | 30.6% | 483.89 |
| FY29 | 30.6% | 631.96 |
| FY30 | 30.6% | 825.34 |
| FY31 | 30.6% | 1077.89 |
| FY32 | 18.3% ·fade | 1275.15 |
| FY33 | 6.0% ·fade | 1351.65 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.